SCHEMBL6982653

SCHEMBL6982653

Cc1nc2ccc(C(=O)C=CC3CCN(Cc4ccccc4)CC3)cc2s1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.67
ACHE P22303 4/20 0.67
HPGD P15428 2/20 0.51
ALDH1A1 P00352 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
LMNA P02545 1/20 0.51
MGLL Q99685 1/20 0.51
HDAC8 Q9BY41 2/20 0.50
ACKR3 P25106 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
GAA P10253 1/20 0.42
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
CHRNA7 P36544 1/20 0.42
CCR1 P32246 1/20 0.41
CCR3 P51677 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982650 1.00 BCHE (0.67) BCHEACHEHPGDALDH1A1SMN1; SMN2
SCHEMBL220379 0.80 ACHE (1.00) BCHEACHE
Hydrochloric Acid SCHEMBL6979927 0.79 ACHE (1.00) BCHEACHE
SCHEMBL5636369 0.79 BCHE (0.71) BCHEACHEHPGDALDH1A1SMN1; SMN2
SCHEMBL5635122 0.79 ACHE (0.74) BCHEACHEHPGDALDH1A1SMN1; SMN2
SCHEMBL6980795 0.78 HDAC8 (0.56) HPGDSMN1; SMN2LMNAHDAC8MEN1
SCHEMBL6980792 0.78 HDAC8 (0.56) HPGDSMN1; SMN2LMNAHDAC8MEN1
SCHEMBL7598871 0.78 BCHE (0.68) BCHEACHEALDH1A1SMN1; SMN2LMNA
SCHEMBL27295449 0.78 BCHE (0.67) BCHEACHEHPGDALDH1A1SMN1; SMN2
SCHEMBL7598867 0.78 BCHE (0.68) BCHEACHEALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0606248-B1 HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS EISAI CO LTD (JP) 2003-03-26 EP disclosed
US-20020049210-A1 Heteroaryl amines as novel acetylcholinesterase inhibitors CHEN YUHPYNG L (US) 2002-04-25 US disclosed
US-6303633-B1 FOR THERAPY AND PROPHYLAXIS OF ALZHEIMER'S DISEASE PFIZER INC 2001-10-16 US disclosed
US-6124321-A Heteroaryl amines as novel acetyl cholinesterase inhibitors PFIZER INC (US) 2000-09-26 US disclosed
EP-0976404-A2 A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal Pfizer Products Inc. (US) 2000-02-02 EP disclosed
US-5965574-A Heteroaryl amines as novel acetylcholinesterase inhibitors CHEN YUHPYNG LIANG (US) 1999-10-12 US disclosed
US-5574046-A Heteroaryl amines as novel acetylcholinesterase inhibitors PFIZER INC. (US) 1996-11-12 US disclosed
WO-1993007140-A1 HETEROARYL AMINES AS NOVEL ACETYL CHOLINESTERASE INHIBITORS PFIZER INC. (US) 1993-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049210-A1 Heteroaryl amines as novel acetylcholinesterase inhibitors ACHE, BCHE, CHAT BCHE 2/4885ACHE 1/4885HPGD 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.